Back to top
more

BeiGene, Ltd. (BGNE)

(Delayed Data from NSDQ)

$191.72 USD

191.72
374,891

-7.72 (-3.87%)

Updated Nov 11, 2019 03:57 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.51%
17.57%
9.27%
4.95%
1.80%
10.51%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | D Growth | D Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights: Navient, BeiGene, SPS Commerce and Chipotle Mexican Grill

The Zacks Analyst Blog Highlights: Navient, BeiGene, SPS Commerce and Chipotle Mexican Grill

SPSC NAVI BGNE CMG

Zacks Equity Research

AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates

AMAG disappoints investors with earnings and sales miss in the third quarter.

AMAG ACOR ANIK BGNE

Zacks Equity Research

4 Stocks to Buy From Sectors With Maximum Job Gains

The American jobs' market added new positions in October at a better-than-expected pace. Here's how to make the most of it.

SPSC GM NAVI BGNE CMG

Zacks Equity Research

Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance

Repligen (RGEN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.

ACOR BGNE ANIK RGEN

Zacks Equity Research

BeiGene, Ltd. (BGNE) is a Great Momentum Stock: Should You Buy?

Does BeiGene, Ltd. (BGNE) have what it takes to be a top stock pick for momentum investors? Let's find out.

BGNE

Zacks Equity Research

Reata Successfully Completes Neuromuscular Disorder Study

Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.

ABBV FCSC RETA BGNE

Zacks Equity Research

BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA

The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.

RHHBY BGNE CELG TEVA

Zacks Equity Research

Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View

Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same.

BGNE RARE FOLD UMRX

Zacks Equity Research

Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates

Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.

BGNE EPZM ACOR ETON

Zacks Equity Research

AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut

AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.

AMAG CGEN BGNE GH

Zacks Equity Research

Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.

BGNE ARNA UTHR GH

Zacks Equity Research

PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y

PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.

PDLI BGNE BIIB EVFM

Zacks Equity Research

Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies

Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.

NVS PFE CNAT BGNE

Zacks Equity Research

Why Earnings Season Could Be Great for BeiGene (BGNE)

BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BGNE

Zacks Equity Research

ArQule (ARQL) to Post Q2 Earnings: What's in the Cards?

On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.

PBYI BGNE NTEC ARQL

Zacks Equity Research

Can Pharmacy Services Drive CVS Health's (CVS) Q2 Earnings?

Akin to the previous quarters, net new business and the steady uptake of Maintenance Choice programs are likely to bolster CVS Health's (CVS) PBM business in Q2.

AVXL BGNE CVS ACER

Zacks Equity Research

Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018

Amicus (FOLD) reports wider-than-expected loss in 2018, while revenues exceed estimates.

BDSI CELG FOLD BGNE

Zacks Equity Research

Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4

Intrexon (XON) incurs narrower-than-expected loss in the fourth quarter of 2018.

CELG ZIOP BGNE XON

Zacks Equity Research

Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat

Horizon Pharma's (HZNP) earnings and sales beat estimates in the fourth quarter of 2018.

CELG BDSI BGNE HZNP

Zacks Equity Research

BeiGene, Ltd. (BGNE) Upgraded to Strong Buy: Here's What You Should Know

BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BGNE

Zacks Equity Research

BeiGene, Ltd. (BGNE) Is Up 12.82% in One Week: What You Should Know

Does BeiGene, Ltd. (BGNE) have what it takes to be a top stock pick for momentum investors? Let's find out.

BGNE

Zacks Equity Research

Can The Uptrend Continue for BeiGene (BGNE)?

Investors certainly have to be happy with BeiGene, Ltd. (BGNE) and its short term performance.

BGNE

Zacks Equity Research

Earnings Estimates Moving Higher for BeiGene (BGNE): Time to Buy?

BeiGene (BGNE) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

BGNE

Zacks Equity Research

BeiGene (BGNE) Catches Eye: Stock Jumps 8.3%

BeiGene (BGNE) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

GILD BGNE

Zacks Equity Research

BeiGene (BGNE): Moving Average Crossover Alert

BeiGene, Ltd. (BGNE) could be a stock to avoid from a technical perspective

BGNE